logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Impacting News

Results From Phase I/IIa Trial of RegenxBio Gene Therapy Product RGX-314

RegenxBio Interim Data from Phase I/IIa Trial of RGX-314 for Wet AMD RegenxBio ( RGNX ) announced interim data from the ongoing Phase I/IIa trial of RGX-314 for the treatment of wet age-related macular degeneration ( wet AMD ). Here...

Read More

October 14, 2019

0

Merck Has Interesting News and Impressive Results

Merck Discontinues Development of COVID-19 Vaccine Candidates Merck ( MRK )  known as MSD outside the United States and Canada announced yesterday that the company is discontinuing the development of its SARS-CoV-2/COVID-19 vaccine candidates, V590 and V591. This decision follows...

Read More

January 26, 2021

0

Aurinia Pharmaceuticals: FDA Approved LUPKYNIS for Active Lupus Nephritis in Adults  

Aurinia Pharmaceuticals LUPKYNIS Approved for LN in Adults Aurinia Pharmaceuticals ( AUPH ) has been granted a U.S. FDA approval of its product LUPKYNIS™ (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active lupus...

Read More

January 27, 2021

0

Hepion Pharmaceuticals' Product CRV431 Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models.

Hepion Pharmaceuticals CRV431 Decreased Liver Fibrosis and Tumor Burden in Experimental Models EDISON, NJ / ACCESSWIRE / October 16, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA ), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...

Read More

October 17, 2019

0

An Acquisition & a Collaboration You Must Know About

Bristol-Myers Squibb Increased activity being observed at Bristol-Myers Squibb ( BMY ) is aimed at further empowering the firm's various franchises. It all started with the firm’s attempt to empower its oncology franchise with the creation and approval of its...

Read More

October 7, 2020

0

Amgen is Still the King of the Biotech Sector

Amgen KRAS Inhibitor, Sotorasib Amgen ( AMGN ) has taken on one of the toughest challenges in the last 40 years when it comes to cancer research by developing the KRAS inhibitor, sotorasib . This product was the first KRAS inhibitor...

Read More

January 30, 2021

0

Filgotinib Has Become Great News for Gilead Sciences and Galapagos NV

Gilead and Galapagos Granted Marketing Authorization for Filgotinib by the EC Gilead Sciences ( GILD ) and Galapagos NV ( GLPG ) were surprised the day the FDA sent them a complete response letter instead of the approval of their...

Read More

October 12, 2020

0

Cytokinetics Product Omecamtiv Mecarbil for Heart Failure with Reduced Ejection Fraction

Cytokinetics Omecamtiv Mecarbil for Heat Failure Three biotech firms: Amgen ( AMGN ) , Cytokinetics ( CYTK ) and Servier worked on the Phase 3 GALACTIC-HF clinical trial to find out whether omecamtiv mecarbil, a product developed by the smallest of...

Read More

October 13, 2020

0

A Great Game Changer for the History of Biotechnology

Intellia Therapeutics Scientific Co-Founder Shares Nobel Prize in Chemistry with Collaborator On October 07, 2020 Jennifer Doudna, Ph.D., one of Intellia Therapeutics ( NTLA ) scientific co-founders, was awarded the 2020 Nobel Prize in Chemistry for the development of the CRISPR/Cas9...

Read More

October 20, 2020

0

Regeneron Has Much Good News. Is the Market Paying Attention?

Regeneron Pharmaceuticals Approval of Evkeeza TM for HoFH Regeneron Pharmaceuticals ( REGN ) has a series of good news that the market does not seem to be aware of as the stock price has yet to react.   On February...

Read More

February 12, 2021

0

  • Previous
  • 1
  • 2
  • ...
  • 13
  • 14
  • 15
  • ...
  • 76
  • 77
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy